^
Association details:
| Biomarker: | ROS1 wild-type |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
Published date:
08/28/2023
Excerpt:
Patients with treatment-naïve stage IIIB/IV or recurrent nsNSCLC without driver mutations in ALK, EGFR, or ROS1, were randomized 1:1 to receive either nivolumab or placebo. Patients in both arms received paclitaxel, carboplatin, and bevacizumab, administered 3-weekly for a maximum of 6 cycles....Nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer OS vs. the placebo combination.
Secondary therapy:
carboplatin + paclitaxel
DOI:
https://doi.org/10.1002/cam4.6348
Trial ID:
